Form 4: Supernus Pharmaceuticals Director Charles W. Newhall III Reports Changes in Beneficial Ownership

Director Charles W. Newhall III reports a transaction involving Supernus Pharmaceuticals common stock and restricted stock units.

Summary

• On February 23, 2024, Director Charles W. Newhall III engaged in a transaction involving Supernus Pharmaceuticals, Inc. (SUPN).
• The transaction involved the disposition of 3,886 shares of common stock following the vesting of restricted stock units.
• Following the reported transaction, Newhall directly owns 120,975 shares of Supernus common stock.
• The restricted stock units vested and were settled in common stock on February 23, 2024.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership by a director, but the overall impact is likely minimal.

Key Dates